Clinical Trial Results

Showing 1-10 of 35

Sorted By:

  • A011401 BWEL (Breast)

    A Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer: Stage II /III within 18 months of diagnosis

  • A011502 ABC Trial (Breast)

    Phase III Randomized double-blind, placebo-controlled trial of aspirin as adjuvant therapy for HER2 Negative breast cancer; STAGE II OR III

  • A011801 CompassHER2-RD (Breast)

    The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DMI and placebo compared to T-DMI and Tucatinib

  • A021502 ATOMIC (Colon)

    A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

  • A031501 AMBASSADOR (Urothelial)

    A Phase III Randomized Adjuvant Study of MK-3475 (PEMBROLIZUMAB) in Muscle Invasive and Locally Advanced Urothelial Carcinoma versus Observation

  • A031704 PDIGREE (Renal)

    PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III trial in Metastatic untreated RENAL Cell CANCER

  • A151216 ALCHEMIST (Lung)

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512

  • A171901 (Lung)

    Older Non-Small Cell Lung Cancer Patients (= 70 Years of Age) Treated with Firstline MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice)

  • A221805 (Peripheral Neuropathy)

    Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

  • DCP-001 (Any Cancer)

    Clinical trial DCP-001 at the Harold Alfond Center for Cancer Care: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)